RUBICON
Micro CapRubicon Research Limited
Pharma
Rubicon Research is an R&D-driven formulations company focused on regulated markets, specializing in complex generics, drug-device combinations, and specialty products. It has full-spectrum capabilities from development to manufacturing and marketing in the US and is expanding into the Indian CNS market.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Mixed fundamentals, management trust is supportive, price trend is neutral, and recent execution is mixed.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Excellent · 100/100Rev +44% YoY · PAT +114% YoY · margin expansion · +8% QoQ · operating leverage
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹514 Cr | +43.6% | +8.0% |
| EBITDA | ₹119 Cr | +65.3% | +10.2% |
| Operating margin | 23.0% | +300 bps | +0 bps |
| PAT | ₹77 Cr | +113.9% | +5.5% |
| PAT margin | 15.0% | +492 bps | -36 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Where growth can come from, and what can break the case
Rubicon Research reported strong Q4 FY26 results with revenue up 43.5% YoY to INR 5,139 Mn, EBITDA up 67.2% YoY to INR 1,213 Mn, and PAT up 111.8% YoY to INR 768 Mn, driven by broad-based growth and stable pricing.
The company delivered robust Q4 FY26 performance with significant YoY growth across key financial metrics. While gross margins faced slight sequential pressure due to increased outsourced manufacturing, management expects EBITDA margins to sustain. Strategic acquisitions and R&D productivity provide future growth visibility.
US Specialty Products
Specialty portfolio contributed 32.8% to gross profit in Q4. Validus markets 3 branded products with no US FDA approved substitutable generics.
Drug-Device Combinations
5 nasal spray products approved. Commissioned one of the largest single-site nasal spray capacities in the world.
R&D Productivity
Incremental revenue multiple on lagging R&D spend increased to 5.9x in FY26, providing strong visibility for FY29/30 & beyond.
India Formulations (CNS)
Arinna Lifesciences acquisition provides a CNS-focused India market launchpad with 60 brands and 4,000 active prescribers.
Pithampur Manufacturing Site
Acquired in FY26. Qualified and product filed with USFDA. Inspection date awaited. Expect to ramp up production in Q1 CY27.
Stable Pricing
Pricing continues to remain stable, driven by the company's focus on specialty/differentiated products.
Benign Macro Environment for India
Company notes a benign macro environment for its India scale-up compared to its US market entry 10 years ago.
Outsourced Manufacturing Reliance
Strong revenue traction requires increased reliance on outsourced manufacturing, which could further contract GM% in the near term.
Gross Margin Pressure
Larger than anticipated reliance on outsourced manufacturing could further contract gross margins in the near term.
Pithampur Commissioning Delay
Delay in USFDA inspection or ramp-up of the Pithampur site could prolong reliance on outsourced manufacturing.
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
YoY comparison is primary for assessing overall growth and annual performance. QoQ comparison is crucial for tracking sequential momentum, especially for gross margin trends, USD revenue growth, and the impact of outsourcing.
Domestic Formulations Growth
Acquisition of Arinna Lifesciences (CNS focused India formulations company) with 60 brands, ~160 sales reps, and 4,000 active prescribers.
US/Export Growth
USD revenue of $56 Mn for Q4 FY26, up 35% YoY ($41 Mn Q4 FY25) and up 4% QoQ ($53 Mn Q3 FY26). ~98% of revenue is USD denominated.
Launch Pipeline & Approvals
Received 12 product approvals in FY26. 24 products were under review by USFDA as of March 31. 92% of approved products are commercialized.
USFDA Observations
Ambernath (OSD, nasal), Satara (oral liquid), Canada R&D, and Thane R&D HQ sites had NAI/VAI with zero observations in recent inspections.
Sustained EBITDA Margin
Management expects Operating EBITDA margin to sustain in the current 22-23% range, even with potential gross margin contraction.
R&D Spend Commitment
Company remains on track for its guided INR 5,000 Mn+ R&D spend over 9 quarters (FY26+FY27+Q1FY28).
Pithampur Ramp-up Impact
Expects production ramp-up from Pithampur in Q1 CY27 to be GM% accretive.
Tactical Manufacturing Measures
Company is evaluating tactical measures to reduce reliance on outsourced manufacturing from a 2-3 quarter perspective.
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Pithampur Production Ramp-up | USFDA inspection awaited, Q1 CY27 ramp-up expected. | Timely USFDA inspection and successful commercialization from Pithampur to reduce outsourcing reliance. |
| Gross Margin Trend | Q4 FY26 GM 66.3%, slight sequential drop due to outsourcing. | Stabilization or improvement in gross margins as own manufacturing capacity comes online and tactical measures take effect. |
| R&D Productivity | Incremental revenue multiple on lagging R&D spend 5.9x in FY26. | Maintenance of R&D productivity at similar levels to ensure strong visibility for future revenues (FY29/30 & beyond). |
| Specialty Gross Profit Contribution | 32.8% in Q4 FY26. | Continued growth in the specialty portfolio's contribution to gross profit, indicating successful execution of strategy. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trend score and candlestick chart
55NeutralSMA20 +47.3% / mo
Technical chart
RUBICONweekly · 5Y+89.2%Technical trend read
Mixed signalsSignals are conflicting — long-term trend unclear. RSI 66. Wait for confirmation.
- SMA20 rising (~32.1% over last month) — short-term momentum positive.
- RSI(14) at 66 — falling, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 15% off 52W high · 105% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
FAIR VALUEWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 8/9.
- Growth contributes 25/25 to the score.
- Quality contributes 18/20 to the score.
Main drags
- Fair-value margin of safety is negative at -86.5%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Cash flow is weaker at 2/10; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Healthy Trust: Claim history is still being built. It ranks around the 90th percentile of the scored universe and 84th percentile within Pharma. No major sub-score weakness stands out.
High Trust Lite: Promoter holding is 59.9%.
Generally investable credibility. Look for weak sub-scores before increasing position size.
overall median 67 · Pharma: 84th pctile, median 70 · Micro: 85th pctile, median 71
0 documents indexed, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Healthy Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 59.9%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.6%.
- ▸ROCE is 26%.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- 78.30
- P/B
- 14.96
- EV/EBITDA
- 44.13
- Market Cap
- 19326.00Cr
Profitability
- ROE
- 27.00%
- ROCE
- 28.40%
- ROA
- 10.61%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 41.00%
- EPS 5Y
- 52.00%
- Revenue 3Y
- 65.00%
- EPS 3Y
- 130.00%
Balance Sheet
- Debt/Equity
- 0.24
- Interest Coverage
- 9.52×
- Altman Z
- 8.29
- Book Value
- 78.20
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 2/5
- OCF
- 205.00 Cr
- EPS TTM
- 14.98
Shareholding
- Promoter Hold
- 59.86%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 75%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.